GLSI NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Greenwich Lifesciences Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 13.50 USD
4.0% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -43.1% below the Trend Line and sits at 21.7% of its 52-week range. The latest completed week returned 4.0%, after a -38.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 61/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.

Setup score 20 out of 100
Latest Close 13.50 USD 31 Jul 2026
1W Return 4.0% latest completed week
4W Return -38.6% short-term follow-through
12W Return -40.9% quarterly tape
Trend Breadth 61.5% 32 of 52 weeks active
Volume Ratio 0.8x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.0% Latest completed week; four-week move -38.6%. Indicator stack 34/17 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.45% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 61/100 51 relevant articles in the latest sentiment read. Event risk 11d Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -43.1% below the Trend Line and sits at 21.7% of its 52-week range. The latest completed week returned 4.0%, after a -38.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2612-week average 0.44

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership7/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.26Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -38.6% over four weeks, -40.9% over 12 weeks, and 21.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W4.0%
4W-38.6%
12W-40.9%
26W-55.1%
52W21.7%
Active trend streak0 weeks
Active weeks in one year32
Trend breadth61.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-1.61Latest activity-pressure read.
Pressure change-44.6%Four-week change in activity pressure.
Leadership-32.57Latest relative-leadership reading.
RS change-586.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength59/100Blend of value, momentum, and quality. Underlying universe rank 42; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality52/100Profitability and accounting quality. Underlying universe rank 49; rank 1 is best.
Momentum54/100Medium-term price momentum. Underlying universe rank 47; rank 1 is best.
Growth54/100Revenue and earnings growth. Underlying universe rank 47; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-50.0%
Gross profit retained from each unit of revenue.
Operating margin
-247797.2%
Operating profit retained from revenue.
Free-cash-flow margin
-359232.3%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-1.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-10.7%
Net share repurchases relative to market value.
Shareholder yield
-10.7%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment61/100

Weighted news tone is neutral across 51 relevant articles.

21 positive · 26 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-60.4%Distance below the 52-week high.
13-week volatility11.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+19.0%Week of 15 May.
Worst week-20.5%Week of 24 Jul.
Latest week+4.0%Week of 31 Jul.

Shape of recent returns

Strong gains8
Modest gains2
Flat weeks0
Modest losses4
Sharp losses12
Recent vol11.6%13-week weekly-return volatility.
Base vol13.5%52-week weekly-return volatility.
Up/down split24/28Count of positive and negative weeks in the 52-week window.
Average skew11.8% / -7.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape23/100

Trend, activity pressure, participation, and risk combine to a 23/100 tape read.

 Indicator analysis37/100

Latest 12-week confirmation: trend 6/12, activity pressure 0/12, relative leadership 7/12.

Activity pressure 0.26; No reversal markers Next-Week ExpectancyNegative 43.45%

Next-week expectancy is negative with a 43.45% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 87; Small Cap Core rank 52 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment61/100

Weighted news tone is neutral across 51 relevant articles.

Understanding the Setup: (GLSI) and Scalable Risk Insiders50/100

No recent insider transaction evidence is stored.

 Earnings11d

Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202613.50 USD4.0%23.73 USD14.26 USD-1.61-32.57600.6KOff
24 Jul 202612.98 USD-20.5%23.93 USD14.24 USD-1.47-34.831.5MOff
17 Jul 202616.32 USD-17.6%24.18 USD14.22 USD-1.48-19.45784.5KOff
10 Jul 202619.80 USD-10.0%24.07 USD14.17 USD-1.33-6.17794.6KOff
3 Jul 202622.00 USD11.1%23.77 USD14.10 USD-1.116.69522.4KOff
26 Jun 202619.80 USD-15.3%23.34 USD14.02 USD-0.99-2.321.0MOff
19 Jun 202623.38 USD-2.8%22.97 USD13.95 USD-0.6711.01395.6KOn
12 Jun 202624.06 USD8.1%22.46 USD13.87 USD-0.4618.46471.2KOn
5 Jun 202622.25 USD-15.0%21.93 USD13.78 USD-0.3613.301.3MOn
29 May 202626.18 USD-5.3%21.48 USD13.71 USD-0.3628.46587.9KOn
22 May 202627.65 USD1.6%20.92 USD13.61 USD-0.4741.25443.3KOn
15 May 202627.21 USD19.0%20.33 USD13.50 USD-0.5542.62915.4KOn
8 May 202622.86 USD-3.5%19.74 USD13.40 USD-0.6021.13521.1KOn
1 May 202623.70 USD-2.1%19.33 USD13.33 USD-0.5033.72520.1KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.